Trxade Health Inc. (NASDAQ: MEDS) is a health service IT company focused on optimizing drug procurement and patient engagement. It helps independent
Trxade Health Inc. (NASDAQ: MEDS) Q1 2022 Research Summary
Categories
pharmaceuticals
PFE Earnings: All you need to know about Pfizer’s Q1 2022 earnings results
Pfizer Inc. (NYSE: PFE) reported first quarter 2022 earnings results today. Total revenues increased 77% year-over-year to $25.7 billion. Reported net income
Earnings: Highlights of Eli Lilly’s (LLY) Q1 2022 results
Eli Lilly and Company (NYSE: LLY) has reported higher earnings and revenues for the first quarter of 2022. The numbers also surpassed
Infographic: Highlights of Intuitive Surgical’s Q1 2022 earnings
Medical device company Intuitive Surgical, Inc. (NASDAQ: ISRG) has reported a decline in first-quarter earnings despite a double-digit growth in revenues, hurt
Abbott Laboratories (ABT) Q1 2022 Infographic: Key financials and quarterly highlights
Abbott (NYSE: ABT) today reported its first-quarter financial results for the period ended March 31, 2022. GAAP net earnings for the first
Johnson & Johnson (JNJ) reports Q1 2022 earnings
Johnson & Johnson (NYSE: JNJ) reported first-quarter 2022 financial results before the regular market hours on Tuesday. The pharmaceutical giant reported revenue
AngioDynamics (ANGO) Q3 earnings beat estimates as sales increase
AngioDynamics Inc. (NASDAQ: ANGO) on Thursday reported higher earnings for the third quarter of 2022 when the medical device maker's net sales
Infographic: Highlights of Cronos’ (CRON) Q4 2021 earnings report
Cronos Group Inc. (NASDAQ: CRON) has reported a wider net loss for the fourth quarter of 2021, despite a double-digit increase in
Infographic: How Tilray (TLRY) performed in Q3 2022
Tilray (NASDAQ: TLRY) reported third-quarter 2022 financial results before the regular market hours on Wednesday. Total net revenue increased 23% year-over-year to
Trxade will stay focused on traditional technology platform for margin growth: CEO Suren Ajjarapu
[caption id="attachment_135351" align="alignnone" width="1280"] Image: iStock[/caption] Can you briefly talk about your business model and the value you add to the market?
Why Intuitive Surgical (ISRG) is a must-own stock after the recent dip
The pandemic had a mixed impact on the healthcare sector. The high demand for COIVD care services sent medical facilities into overdrive,
HEXO Earnings: Highlights of Hexo’s Q2 2022 financial results
Cannabis producer HEXO Corp. (NASDAQ: HEXO) has reported a wider net loss for the second quarter of 2022. However, the Canada-based company's
Cipher Pharmaceuticals Inc. (CPH) Q4 2021 Earnings Call Transcript
Cipher Pharmaceuticals, Inc. ( TSX: CPH) Q4 2021 earnings call dated Mar. 18, 2022 Corporate Participants: Craig Mull -- Interim Chief Executive Officer Scott
Should you invest in Walgreens Boots Alliance ahead of earnings?
Walgreens Boots Alliance, Inc. (NASDAQ: WBA) has been busy enhancing its capabilities in healthcare delivery lately, through various initiatives including M&A deals.
ANI Pharmaceuticals, Inc. (ANIP) Q4 2021 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) Q4 2021 earnings call dated Mar. 15, 2022 Corporate Participants: Judy DiClemente -- Investor Relations Nikhil Lalwani -- President and Chief
AN2 Therapeutics takes IPO route to advance pipeline. Here’s all you need to know
After starting the year on a high note, the IPO market is currently going through a slow phase mainly due to the
Meihua’s IPO might set the stage for revival of Chinese listings in the US
Meihua International Medical Technologies is the latest healthcare company to seek Wall Street listing, even as the IPO market picks up momentum
Infographic: Everything you need to know about Aurora Cannabis’ (ACB) Q2 earnings
Aurora Cannabis, Inc. (NYSE: ACB) on Thursday reported a narrower net loss for the second quarter of 2022. The company's revenues dropped
Infographic: Highlights of Canopy Growth’s (CGC) Q3 2022 earnings
Cannabis producer Canopy Growth Corporation (NASDAQ: CGC) reported a narrower net loss for the third quarter of 2022, despite an 8% decrease
PFE Earnings: All you need to know about Pfizer’s Q4 2021 earnings results
Pfizer Inc. (NYSE: PFE) reported fourth quarter 2021 earnings results today. Revenues doubled year-over-year to $23.8 billion. Excluding contributions from Comirnaty and
Ocean Biomedical slashes IPO size. Should you invest in the stock?
The biomedical industry grew at an accelerated pace in 2021 even as healthcare systems went into overdrive amidst the COVID-induced medical emergency.